The rosemary plant, Rosmarinus officinalis L (family Lamiaceae), is an aromatic evergreen shrub originating in the Mediterranean region and now growing widely in Europe, Asia, and Africa (Figure 1). The genus name Rosmarinus is derived from the Latin “Dew of the Sea” and has traditionally been associated with remembrance, love, and fidelity.1,2 This plant has been used extensively as a culinary spice in a variety of contexts. In Mexico, it is used in preparation of tea, and it seasons meats in the cuisines of Europe and the Middle East. Another use of rosemary is as part of a marinade for lamb, pork, and chicken dishes. Rosemary leaves flavor soups and beverages in India. Finely minced leaves can enhance stews, casseroles, fish, potatoes, salads, pasta, and breads such as focaccia. Rosemary and its extracts also are used as food preservatives and enhancers of sensory and functional properties.1–3 In the European Union, rosemary extracts are approved as an additive in a variety of products.4 Furthermore, rosemary and its constituents have been incorporated into cosmetics and cosmeceuticals in the hope of enhancing the health of skin and hair.5–8 For centuries, this plant has been an ingredient in folk medicines with associated claims for relief of such diverse symptoms and conditions as dysmenorrhea, mental decline, epilepsy, pain relief, and infertility, to name a few.1,2 It also has been promoted as a treatment for hair loss, dyspepsia, dermatitis, anxiety, cognitive improvement, constipation, joint and muscle pain, and improvement of circulation.1,2,9 Today, research attention is focusing more closely on whether this herb may have potential to alleviate complications of obesity and diabetes, inflammation-associated conditions, and neurological deficits.
Rosemary and its constituents have been the subject of considerable research interest because of their potential antioxidant, anti-inflammatory, and neurological activities,1,2,8,10 some of which are discussed in this article. In this overview, reports from in vitro and in vivo studies are discussed separately. Similarly when considering each health effect of rosemary, data from experiments examining the essential oil and extracts, as well as individual rosemary phytochemicals, are presented separately. Data from animal studies in which different delivery systems are used (topical, oral, injectable) may be included together in a section but are not necessarily directly comparable. For the sake of brevity, some cell culture and experimental animal studies are contained in the Appendix (Supplemental Digital Content 1, http://links.lww.com/NT/A15). Figure 2 provides chemical structures of several major rosemary constituents.
COMPOSITION AND BIOAVAILABILITY
The referenced studies evaluate the effects of diverse rosemary samples, including its dried powder, essential oil, and water and organic solvent extracts. Although the composition of these oils and extracts can vary widely depending on the specific preparation protocols used, the growth conditions of the plant, and the specific portion of the plant selected, some general descriptions of content can be noted. For example, the essential oil of rosemary may contain 6% to 41% 1,8-cineole, 18–28% camphor, 9% to 14% α-pinene, and 4% to 10% borneol. Several different essential oil chemotypes of indigenous and cultivated plants exist. Each essential oil from these has a different composition and thus potentially different biological activity.11–13 An ethanol extract of rosemary was reported14 to contain (mg/g dry extract) rosmarinic acid (RA; 11.6), rosmanol (34), carnosol (22), and CA (177). An acetone extract contained as major constituents RA, carnosol, carnosic acid (CA), methyl carnosate, and 12-methyl CA.15 A water extract has been reported to contain 1,8-cineole, camphor, borneol, and 2-carene as major ingredients.16 A methanolic extract consisted of carnosol and CA as major diterpenes, hesperidin and genkwanin as major flavonoids, and RA and gallic acids as major phenolic acids.17 The variety of extract compositions reported underscores the need to characterize the phytochemical profile of rosemary samples used in preclinical and clinical studies in order to better compare studies and to more fully determine the role of bioactive constituents contributing to a biological action.
Rosemary and other spices in the Lamiaceae family are well-known sources of diverse natural antioxidants.18,19 Several extracts of rosemary have been prepared for commercial use as food flavorings and antioxidant preservatives. The European Food Safety Authority (EFSA) has published detailed comparative profiles of these extracts.20 The principal antioxidant components of these extracts and the most widely studied of rosemary constituents are the phenolic diterpenes CA21 and its main breakdown product carnosol and the caffeoyl derivative RA (Figure 2).1,22–28 Seasonal variations, storage conditions, drying processes, and extraction procedures can substantially impact the balance of rosemary bioactive chemicals in a final product. Choice of solvent, culture medium, temperature of biological experiments, and exposure to light will modify effective concentrations of active rosemary constituents in studies of its health benefits.3,29–32
Unfortunately, the systematic characterization of major rosemary constituents’ bioavailability in animals and humans is incomplete. The oral bioavailability of rosemary bioactive constituents can affect systemic exposure and biological outcomes and is an important factor in determining their potential health effects.
In humans, it was reported that, following acute oral dosing with an extract of Perilla frutescens leaves containing 200 mg RA, a plasma RA concentration of 1.15 μM was achieved.33 A placebo-controlled trial was conducted with 11 healthy individuals receiving 100, 250, or 500 mg RA administered in an extract of Melissa officinalis.34 Participants were evaluated in both fasting and fed states. Maximum serum concentration of RA for those fasting and given 250 and 500 mg RA was 72.2 and 162.2 nmol/L, respectively. Food intake increased the exposure of RA and delayed absorption. In another study, normal subjects were fed 2.8 g/d of rosemary powder for 7 days, and blood subsequently drawn.35 Although levels of rosemary constituents were not measured in the blood, some rosemary components were sufficiently bioavailable so that, compared with controls, serum markers of inflammation were significantly suppressed. It is evident from these findings that in order to better understand the potential human health benefits of these rosemary constituents the impact of various oral doses, length of exposure, and presence of other dietary factors on the bioavailability and metabolism of CA, RA, and other prominent rosemary phytochemicals need to be more thoroughly assessed in humans. Additional bioavailability information from experimental animal studies is presented in the Appendix (Supplemental Digital Content 1, http://links.lww.com/NT/A15).
SCIENTIFIC EVIDENCE FOR SELECT POTENTIAL BENEFITS
Rosemary Extracts and Essential Oil
Rosemary has been identified as a source of nutraceutical phytochemicals for potential use as neuroprotective agents.36 Compared with that for individual rosemary constituents (see Appendix, Supplemental Digital Content 1, http://links.lww.com/NT/A15), fewer studies have evaluated rosemary oil or extracts for neuroprotective actions. Some reported effects are inconsistent. For example, in an in vitro study, an undefined methanol extract protected human neuronal cells from the oxidative stress and apoptosis accompanying H2O2-induced injury.37 On the other hand, rosemary oil (2.5–10 mM) was ineffective in protecting cultures of PC12 cells from neurotoxicity induced by l-glutamate and N-methyl-4-phenylpyridinium ion.38
In a mouse model of pentylenetetrazol-induced seizures, rosemary essential oil (1.61 mL/kg, intraperitoneally) produced a small but significant increase in seizure latency and improved survival.39 This oil was analyzed to contain 45% 1,8-cineole, 14% α-pinene, and 9% borneol. In a rat model of neuronal cell death and brain damage, animals were fed diets supplemented with ground rosemary (1% and 2% wt/wt) for 6 weeks prior to dosing with CCl4.40 Feeding rosemary resulted in a significant 22% and 33% reduction in CCl4-induced tissue-type plasminogen activator levels in brain homogenates for rats fed the 1% and 2% diets, respectively, compared with controls. The authors suggested that rosemary lessened tissue-type plasminogen activator–associated extracellular proteolytic activity linked to the chemically induced brain damage.
Rosemary Essential Oil
In a human randomized, crossover study (26 subjects), inhalation treatment with rosemary essential oil was evaluated for improvement of sensory ratings for several types of pain (contact heat, pressure, and ischemic pain). Compared with controls, rosemary inhalation did not affect quantitative pain sensitivity ratings, but did retrospectively reduce subjects’ global impressions of pain intensity and unpleasantness, although only marginally. The authors concluded that this aromatherapy produced a benefit not through direct analgesic effects but rather “by providing a competing pleasant sensory and affective experience that can alter retrospective pain evaluation.”41 The practical significance of this response is unclear.
A human open-label, 8-week observational trial investigated the pain-diminishing efficacy of a proprietary natural product formulation (Meta050) at doses varying from 440 mg (3 times per day) to 880 mg (twice per day) in 54 patients with arthritis or fibromyalgia. This Meta050 formulation was composed of iso-α acids from hops, a rosemary extract, and oleanolic acid. There was evidence that Meta050 alleviated indices of pain for arthritis patients, but not for those with fibromyalgia.42 The basis for this differential benefit was not determined. The contribution of rosemary extract individually to this effect cannot be determined. However, evaluating the separate action of rosemary in alleviating symptoms of these 2 patient groups is worth pursuing.
Cognition and Mood Benefits
It is not surprising that rosemary would have cognitive benefits in light of its ancient use for memory enhancement by Greek and Roman students prior to examinations by rubbing its oil into their temples and foreheads.43
Rosemary Essential Oil
Rosemary essential oil has been shown to elicit physiological responses and changes in mood in several human aromatherapy studies. For example, 22 healthy volunteers sniffed rosemary oil aroma for 5 minutes. Saliva subsequently was collected, and free radical–scavenging activity and the levels of the stress hormone cortisol were measured. Inhaling the rosemary aroma increased scavenging activity values and decreased cortisol levels. A significant inverse correlation was observed between scavenging values and cortisol levels at each rosemary concentration tested.44 In another investigation, a quasi-experimental design with pretest and posttest measures was used to determine the effect of rosemary essential oil inhalation on test-taking anxiety among graduate nursing students. Test-taking stress was reduced by exposure to rosemary oil sachets, and it was determined that pulse rate also decreased significantly among students compared with controls.45 In contrast, in another student study, exposure to rosemary scent prior to an anxiety-provoking task actually was associated with higher tension-anxiety scores and higher confusion-bewilderment ratings among participants, compared with controls. The authors suggested that, in this context, the magnitude of the rosemary scent may have overstimulated the subjects.46 Several additional reports evaluated the impact of rosemary aromatherapy on cognition and mood. For example, individuals exposed to rosemary aroma showed increased alertness and a decrease in frontal α power as measured by electroencephalography (EEG), a result consistent with a higher level of alertness. Participants inhaling rosemary aroma also reported being less anxious and more relaxed and were noted to perform math computations faster but without better accuracy.47 In another study using EEG monitoring, the effect of exposure to rosemary scent was measured by determining the relative left frontal EEG activation, an indication of composed mood, in contrast to that for right frontal activation. For both adults and infants as subjects, those with greater relative right frontal EEG activation at baseline (higher anxiety and depression) benefited the most from exposure to rosemary.48 In a similar manner, another investigation evaluated the effect of rosemary oil inhalation on subjective feelings and nervous system activities.49 Healthy subjects (n = 20) were administered 10% vol/vol rosemary oil using an oxygen pump connected to a respiratory mask for 20 minutes. After rosemary oil inhalation, there were significant increases in blood pressure, heart rate, and respiratory rate. Moreover, based on EEG and autonomic nervous system recordings, there was a reduction in the power of α1 and α2 waves and increased β activity in the anterior region of the brain. The oil consisted of 19.4% α-pinene, 20% 1,8-cineole, and 21.3% camphor. These results suggest that stimulatory effects occur following rosemary oil inhalation. The olfactory property of rosemary essential oil on cognitive performance and mood was also evaluated in 48 participants performing a computerized cognitive assessment battery. Rosemary produced a significant improvement in memory performance, compared with controls, although there was decreased memory speed. Rosemary also was reported to enhance alertness and contentment in those participating.50 A mechanism for this rosemary-associated memory benefit was not determined. In a more recent report, 23 students participated in a study to investigate the relationship between ambient odor and memory. It was found that rosemary was effective as a memory cue in retrieval of information. However, its benefit may not have been due to any specific component but to a nonspecific cue related to its perception as unpleasant and distinctive.51
Lastly, a benefit of aromatherapy was tested in 28 elderly patients with dementia. A crossover method was used to measure the effect of exposure to several essential oils. Odors of oil-impregnated gauze diffused with an electric fan were evaluated for effects on multiple functional assessment tests for Alzheimer disease and dementia. In 1 protocol, patients were exposed for 28 days to lemon and rosemary oils for 3 hours in the morning and to lavender and orange oils for 1.5 hours in the evening. This aromatherapy regimen significantly improved cognitive function, although the magnitude of any individual contribution from rosemary oil cannot be assessed.52
Collectively considering these human inhalation studies, it would be helpful for future studies not only to better quantitate doses of oil inhaled, but also to measure internal levels of absorbed rosemary oil chemical constituents that could be used as markers of exposure among subjects. For example, blood levels of myrcene, 1,8-cineole, or α-pinene might be considered for this purpose.
One short-term clinical study (randomized, placebo-controlled, double-blind, repeated-measures, crossover study design) evaluated the effect of powdered rosemary-containing tomato juice on cognitive function in an elderly population.53 This rosemary sample consisted of the volatile oil constituents 1,8-cineole (0.57%) and borneol (0.14%) and α-pinene (0.13%), as well as the nonvolatile components RA (1.5%), CA (1.7%), and ursolic acid (2.9%). Tomato juices containing 4 rosemary doses (750–6000 mg) were given acutely to 27 older adults 1 to 6 hours prior to testing with the Cognitive Drug Research computerized assessment system. Doses were counterbalanced, and there was a 7-day washout between visits. A significant biphasic effect on speed of memory was apparent, with the 750-mg dose yielding a beneficial response and the 6000-mg dose a detrimental effect. A similar biphasic effect was noted for self-reported alertness, compared with controls. Two measures were not affected by treatment (power of attention and quality of episodic memory), whereas 2 other measures (continuity of attention and quality of working memory) were impaired by rosemary treatment, although for these latter 2 measures dose-specific effects were not evident.53 The authors noted that the dose nearest to culinary consumption (750 mg) benefited speed of memory, which indicates that longer-term studies measuring cognitive functions would be very worthwhile to conduct. In contrast, capsules containing a total of 6.8 g rosemary were ingested by young adults (n = 40) 1 hour prior to administration of cognitive, motivation, and mood tests.54 The rosemary sample was analyzed to contain 20 mg RA/g. It was determined that rosemary did not induce consistent short-term improvements in attention, cognitive motivation, or feelings of mental energy or fatigue in these young adults with low energy. Additional neurological actions of rosemary and its constituents are detailed in the Appendix (Supplemental Digital Content 1, http://links.lww.com/NT/A15).
Rosmarinus officinalis L (crushed and encapsulated) was given orally (2.8 g/d) to 12 subjects for 7 days.35 Human serum isolated from these subjects was added ex vivo to cultures of oxidized low density lipoprotein (oxLDL)-stimulated THP-1 human monocytes. Serum from those fed rosemary showed significantly lower expression of inflammatory markers interleukin 6 (IL-6) and tumor necrosis factor α, compared with controls. These findings suggest that the rosemary constituents were sufficiently bioavailable so that subjects’ serum samples had a significant impact on THP-1 inflammatory markers. No adverse effects were noted.
Rosemary Essential Oil
Several studies have shown anti-inflammatory effects of rosemary essential oil. Compared with controls, oral treatment of rats with the oil (250–750 mg/kg [unless otherwise indicated, mg/kg refers to mg sample/kg body weight]) 30 minutes prior to injection of paws with carrageenan significantly inhibited paw edema at a rate similar to that of the drug indomethacin given at a dose of 5 mg/kg. In contrast to indomethacin, which inhibited only edema, the essential oil (500 mg/kg) also reduced the volume of pleural inflammatory exudate and suppressed the number of migrated cells.55 This oil’s major constituents were 25% myrcene, 20% 1,8-cineole, and an unidentified terpene (20%). In a study using essential oil containing α-pinene (17%), 1,8-cineole (16%), camphor (28%), and β-myrcene (10%), an in vivo leukocyte migration assay was used to evaluate the anti-inflammatory effects of the essential oil.56 This oil was administered to mice (125–500 mg/kg, orally) prior to carrageenan injection into the scrotal chamber. For those given the oil, there was a significant reduction in the number of leukocytes that rolled, adhered, and migrated to the scrotal endothelium, compared with controls. In addition, cultures of leukocytes were obtained from the carrageenan-treated mice and were exposed in vitro to the essential oil (10−4 to 10−2 μL/mL). The oil caused a significant reduction of leukocyte migration toward a casein stimuli, compared with controls. The authors suggested that rosemary essential oil’s anti-inflammatory action is due to its inhibition of leukocyte chemotaxis and leukocyte-endothelial cell interactions in the microcirculatory network. In another mouse study, a mixture of rosemary volatile constituents (43% 1,8-cineole, 41% camphor, 14% limonene, 2.5% borneol, 0.5% α-pinene) was administered intratracheally (4.6 μg) to mice 3 hours before intratracheal instillation of 500 μg of suspended diesel exhaust particles.57 Compared with particle-treated controls, after 24 hours, the oil extract significantly inhibited particle-induced lung inflammation and suppressed the expression of macrophage inflammatory protein 1α, macrophage chemoattractant protein 1, and keratinocyte chemoattractant. Interleukin 1β expression was not suppressed. Moreover, the beneficial effect of the rosemary oil–derived mixture appeared not to be mediated by suppression of 8-hydroxyguanosine- and nitrotyrosine-mediated oxidative stress. In a second study,58 using this oil mixture, mice were treated with 1 μg of house dust mites by intratracheal cannula 4 times weekly. The rosemary oil preparation at 2 doses (9.6 and 46 μg/mouse) was administered 7 times weekly for 6 weeks. Treatment of mice with this oil preparation inhibited house dust mite–induced pulmonary eosinophilic inflammation and IL-13 expression, a critical mediator of airway inflammation. In light of these findings, the authors suggested that this extract could be considered for supportive therapies of airway diseases such as asthma.
Extracts of Rosemary
Limited human data are available regarding use of rosemary extract. A proprietary formulation containing reduced iso-α acids from hops, a rosemary extract, and oleanolic acid was given (1320-1760 mg/d) to patients (open-label, observational 8-week study) with rheumatic disease. A trend toward decreasing levels of C-reactive protein in blood was observed for those subjects initially presenting with elevated C-reactive protein.42 The individual contribution of rosemary cannot be determined. In another study of 56 osteoarthritis patients, a similar phytochemical combination, when given orally for 4 weeks (600 mg/d), decreased reports of disease symptoms in patients with osteoarthritis.59 A randomized double-blind study of 62 individuals with medically diagnosed knee osteoarthritis was conducted to evaluate the effects of a high RA spearmint tea.60 For 16 weeks, participants in the treatment group consumed 2 cups of tea/d, which contained 130 to 150 mg RA/cup, and controls consumed 13 mg RA/cup of tea. Pain scores significantly decreased for the high-RA group, compared with controls, and there was improvement in physical function as measured in the 6-minute walk test.
In a human study of subjects with mild atopic dermatitis, topical application of RA (0.3% cream emulsion) twice a day for 8 weeks to elbow flexures significantly reduced erythema and transepidermal water loss on the antecubital fossa, compared with cream controls.61 Treated subjects also self-reported noticeable improvements in dryness and pruritus. A randomized, double-blind, age-matched, placebo-controlled clinical trial was conducted with patients with seasonal allergic rhinoconjunctivitis who were treated orally with RA (50 mg/d or 200 mg/d) for 21 days.62 Based on patients’ daily records, compared with controls, those treated with 50 mg RA exhibited significantly improved symptoms for itchy nose, watery eyes, and itchy eyes. Rosmarinic acid also significantly reduced the numbers of neutrophils and eosinophils in nasal lavage fluid. Neither adverse events nor significant abnormalities in blood tests were detected. These results were similar to those reported by the same authors when patients with seasonal allergic rhinoconjunctivitis were treated orally with an extract of P frutescens enriched for RA (50 or 200 mg RA) daily for 21 days.63
In a recent double-blind, placebo-controlled study, 242 patients with chronic obstructive pulmonary disease were randomly assigned to receive 200 mg 1,8-cineole or placebo, orally 3 times per day for 6 months.64 Compared with controls, those treated with 1,8-cineole showed a significant drop in frequency, severity, and duration of respiratory problems, and, secondarily, lung function and quality of life were significantly improved. Adverse events were comparable in both groups. In another double-blind, placebo-controlled trial, 32 patients with steroid-dependent bronchial asthma were randomly allocated to take small capsules containing 200 mg 1,8-cineole 3 times a day or placebo for 12 weeks.65 For those receiving 1,8-cineole, there was a significant reduction in oral steroid doses needed to maintain clinical stability. No serious adverse events were reported. Two earlier studies by the same researchers suggested that the effects of 1,8-cineole may be mediated by suppression of cytokine production and arachidonic acid metabolism.66,67 The appendix contains more findings on anti-inflammatory actions of rosemary68 (see Appendix, Supplemental Digital Content 1, http://links.lww.com/NT/A15).
Alleviation of Metabolic Disorders (Obesity and Diabetes)
Several studies show consistent effects of rosemary extracts on signs of diabetes and the metabolic syndrome. In normoglycemic mice provided a water extract of rosemary (10 g/L) in place of tap water, plasma glucose levels decreased a significant 12% after 3 months, compared with controls. For alloxan-treated hyperglycemic mice consuming the same water extract for 1 month, plasma glucose levels significantly decreased by 45%.69 No toxic effects during chronic application were noted, and no mechanisms for this hypoglycemic effect were identified. Two experiments with rosemary were reported for normal and alloxan-induced rabbits. An undefined ethanol extract of rosemary administered orally to fasting normal rabbits (100–200 mg/kg) produced a significant drop in blood glucose levels of up to 21% within 6 hours, without changing insulin levels. In alloxan-treated rabbits, dosing with this extract (100–200 mg/kg, orally) for 8 days produced a significant decrease in blood glucose and an increase in serum insulin levels, compared with controls, an effect determined in part to be due to the extract’s potent antioxidant activity.70 The authors speculated that the elevation of circulating insulin levels in the rosemary-treated alloxan-diabetic rabbits could be due to components that either protect functional β cells from additional damage or stimulate regeneration of β cells. These possibilities need to be further examined. A recent study found that combining treatment of streptozotocin-induced diabetic rats with an aqueous extract of rosemary (200 mg/kg per day, intragastrically) with a regimen of endurance exercise for 8 weeks resulted in lowered blood indices of oxidative stress by enhancing antioxidant enzyme activates and decreasing lipid peroxidation levels approaching normal levels seen in healthy controls.71 In 2 rodent experiments, a rosemary extract rich in CA was evaluated. Mice were provided for 16 weeks a high-fat diet supplemented (500-mg/kg diet) with a rosemary extract standardized to 20% CA. Diet supplementation with the extract decreased fasting blood glucose and plasma cholesterol levels, compared with controls.72 Moreover, body and epididymal fat weights for mice fed the rosemary supplemented high-fat diets were less than those for mice fed the control high-fat diet. The authors suggested that this effect may partly be associated with activation of peroxisome proliferator-activated receptor γ. In a second investigation, an ethanol extract of rosemary containing 39% CA, 6.5% carnosol, and 6.9% methyl carnosate was added to diets (0.5% wt/wt) of lean and obese Zucker rats for 64 days.73 Compared with controls, the rosemary-supplemented diet moderated the weight gain of both groups of rats without affecting food intake. Moreover, primarily in the lean rats, the plasma lipid profile was improved. This diet significantly inhibited gastric lipase and thus was hypothesized to reduce fat absorption. Of note is that animals consuming rosemary extract exhibited increased liver weights and enzymatic activities, a response to rosemary extract reported by others.74,75 The authors suggested that long-term consumption of rosemary extracts rich in CA may be beneficial for weight maintenance and normalization of lipid profiles. However, the consequences of increased liver weight and liver enzyme induction would need to be better characterized. This report led to a subsequent opinion article suggesting that CA should be considered for the treatment of nonalcoholic liver disease or the metabolic syndrome.76 Of additional interest, an ethanol extract of rosemary (39% CA, 7% carnosol) was supplemented to diets (0.5% wt/wt) for 64 days to both lean and obese Zucker rats.77 Compared with controls, feeding of the extract to lean rats led to an increase in circulating adiponectin in contrast to that seen for obese rats in which feeding of the extract resulted in decreased circulating adiponectin. In lean rats, consumption of the rosemary extract led to a significant decrease in circulating IL-1β and tumor necrosis factor α, compared with controls, in contrast to that for obese rats in which no changes were noted. Activated AMP-activated protein kinase in perivisceral adipose tissue of rosemary fed rats was significantly decrease in obese rats, whereas no effect of dietary supplementation was seen for lean rats. Based on the observation that AMP-activated protein kinase may mediate the metabolic effects of leptin and adiponectin, the authors speculated that a functioning leptin signaling pathway is required for the rosemary extract to exert metabolic regulatory effects on obese Zucker rats. A recent study using cultures of human primary omental preadipocytes and adipocytes found exposure to rosemary extract modulated adipocyte differentiation and interfered with adipogenesis and lipid metabolism.78 In a similar feeding study by the same authors,79 dietary supplementation with rosemary extract decreased cecal Lactobacillus/Leuconostoc/Pediococcus groups and increased Blautia coccoides and Bacteroides/Prevotella groups, compared with controls, for both lean and obese Zucker rats. The metabolic consequences of these microbial population changes in the gut are not clear. Furthermore, extract supplementation increased short-chain fatty acid excretion in the feces of obese rats but decreased excretion in lean rats, compared with their controls, which, according to the authors likely reflects differential uptake and metabolism of short-chain fatty acid between the lean and obese animals. In another study,80 mice were fed for 50 days an ethanol extract of rosemary that was added to high-fat diets at 0.025% wt/wt (20 mg/kg body weight) and 0.25% wt/wt (200 mg/kg body weight). This extract contained 5.6% carnosol, 2.5%, CA, and 4% RA. The animals fed the higher dose of rosemary extract gained less weight and had a 57% reduction in fat mass accrual, compared with controls, effects coinciding with increased fecal lipid excretion and lower pancreatic lipase activity. Hepatic triglyceride levels were decreased by 39% in the rosemary-treated mice. In contrast to other reports, rosemary supplementation had no significant effect on the intraperitoneal glucose tolerance test and fasting insulin levels in this study. The authors suggested that rosemary extract may have potential use in strategies to limit weight gain and liver disease associated with obesity. In another study, a rosemary extract enriched for CA was given to C57BL/6J mice as part of either a high-fat diet or a high-fat diet supplemented with either 0.14% or 0.28% (wt/wt) CA-enriched extract for 16 weeks.81 Supplementation of diets with rosemary extract significantly reduced body weight gain, percent body fat composition, plasma transaminases, glucose and insulin levels, and liver triglycerides, compared with the high-fat controls. Moreover, in similar comparisons among groups, liver peroxidation and lipid accumulation were decreased for the mice fed the rosemary supplemented diets, and fecal lipid excretion was elevated, compared with controls. The authors concluded that the CA-enriched rosemary extract dose-dependently suppressed obesity and metabolic syndrome induced by a high-fat diet in mice. These results are similar to those reported Park and Sung82 in these mice. A recent review highlighted the potential benefits of rosemary in preventing obesity and the metabolic syndrome.83
The effect of a natural product mixture containing 0.02% rosemary extract on urine metabolite profiles of diabetic humans was reported.84,85 Although some treatment-related effects were observed, interpretation of the urine patterns was not entirely straightforward, and further exploration of these profiles and the metabolic changes they reflect is needed. The authors subsequently provided a detailed strategy for obtaining urine fingerprints from metabolomics data.86 In another trial, a high antioxidant spice blend in which rosemary was 1 of 9 spices attenuated postprandial insulin and triglyceride responses when fed to overweight men (randomized controlled, 2-period crossover study). The individual contribution of rosemary to this benefit, however, cannot be determined but deserves further study.87 Additional reports about effects of rosemary on metabolic disorders are described in the Appendix (Supplemental Digital Content 1, http://links.lww.com/NT/A15).
Several actions of rosemary are evident that warrant further confirmation. First, neurological benefits do occur when rosemary extracts and individual constituents are administered orally in animal models. Oral administration of RA and CA in animal models is associated with neuroprotective effects and actions in the brain. Oral dosing with rosemary oil and rosemary extracts in several animal models of pain leads to antinociceptive responses, although it is unclear which individual constituents contribute to these actions. Aromatherapy with rosemary oil in humans is associated with changes in mood and physiological measures of anxiety and alertness. Oral RA improved cognitive performance in animal models, whereas oral rosemary oil and rosemary extract produced antidepressant-like activities in several in vivo models. Multiple constituents of rosemary likely contributed to these latter effects, although oral RA elicited antidepressant-like responses when given alone. Individual rosemary phytochemicals do not always exhibit similar responses when different neurological end points are measured. For example, RA may be active in an amyotrophic lateral sclerosis (ALS) transgenic mouse, but have no effect in a rodent pain model. This suggests that, although identifying specific rosemary phytochemicals that are biologically active is important for mechanistic characterizations, the mix of constituents in rosemary is likely to have a broader impact on health end points than 1 component alone. Moreover, examining rosemary’s effects on neurological end points at lower doses approximating dietary exposures in humans would certainly be worthwhile. Comparisons of findings between animal studies are often difficult not only because of dosing and sample identity disparities, but also because recognized markers of rosemary bioavailability are not reported. Future rosemary feeding studies in animals evaluating neurological benefits need to identify and measure chemical profiles in the blood and brain associated with rosemary exposure and bioavailability. For example, 1,8-cineole could be measured when essential oils are administered, or, similarly, total CA and CA-glucuronides could be measured when water or alcohol extracts of rosemary are used.
Reports of rosemary’s anti-inflammatory actions, particularly following oral exposure in animals, provide emerging evidence that rosemary essential oil, rosemary extracts, and individual constituents can improve diverse respiratory, vascular, and dermatological conditions. Rosmarinic acid and 1,8-cineole in particular have demonstrated potential benefits in human studies evaluating skin and respiratory responses, respectively.
Evaluation of different rosemary samples provided mixed evidence of efficacy in improving symptoms of metabolic disorders. For example, oral rosemary oil elicited inconsistent effects on blood glucose levels in several animal models. In contrast, water and alcohol extracts of rosemary provided orally to normal and diabetic animals resulted in hypoglycemic responses, improved blood lipid profiles, and lower weight gains. Oral CA in particular was associated with hypoglycemic and antiadipogenic responses. Besides further confirmation of the extracts’ effects on these end points and identification of the active constituents, an assessment of rosemary’s effects on satiety, energy balance, and body weight regulation also would be worthwhile, especially when provided at levels consistent with amounts typically consumed by humans.
Rosemary consumed in usual culinary contexts or as an approved food additive is considered generally recognized as safe by the US Food and Drug Administration.9,20 Rosemary essential oil has been recognized by the US Food and Drug Administration as generally recognized as safe for its intended use as a food additive. Rosemary extracts have been used for more than 20 years by the food industry as a flavoring and preservative. Also, in 2010, the European Commission classified rosemary extracts as food additives to be produced by specific extraction processes with defined standards of purity. Japan and China also list rosemary extracts as approved food additives.20,21 Both acute and subchronic toxicity studies for rosemary extracts and select individual phytochemicals have been published.20,73,88,89 Of particular relevance is a summary of toxicology tests in rodents that was provided by the EFSA in which several types of rosemary extracts were evaluated at multiple doses.20 As summarized in this report, subchronic studies at the highest doses of rosemary extract tested (320 mg/kg body weight per day or 5000-mg/kg diet) showed that the only adverse effect was a slight increase in relative liver weights, which was reversible and assessed not to be of toxicological concern. Based on these studies, the EFSA determined that the NOAEL (no-observed-adverse-effects level) for intake of these rosemary extracts is 180 to 400 mg extract/kg body weight per day, which was estimated to correlate to approximately 20 to 60 mg total CA and carnosol/kg body weight per day. For purposes of comparison, it has been estimated that adult dietary exposure in the United Kingdom to total rosemary-derived CA and carnosol present in approved food additives is likely to be approximately 0.04 mg/kg body weight per day.20 This estimate did not include background culinary use, which was considered not to be regular or chronic. Consumption data for culinary use of rosemary are not available, although dried rosemary use in cooking in the United Kingdom is estimated to be 0.4 to 2.5 g/serving, which would translate for a 60-kg person to 5 to 40 mg rosemary/kg body weight or 0.1 to 0.8 mg/kg body weight of carnosol plus CA.20 These values can be used in considering amounts of rosemary to use in human studies. Based on these toxicity data and on the estimated large margins of safety, the EFSA considered that the expected dietary exposure to rosemary used as an additive does not pose a safety concern.
In animal studies discussed in this overview, the oral dosing protocols used for many of the experiments often approached the NOAEL determined by the EFSA. For example, in some cases, extracts of rosemary were administered orally at levels up to 200 to 300 mg/kg and CA doses up to 20 mg/kg. On the other hand, there were studies that found biological activity at less than or equal to 100 mg/kg rosemary extract orally and less than or equal to 10 mg/kg CA orally or when CA was supplemented to diets at less than or equal to 0.05% wt/wt. These latter studies suggest that measurable biological effects of rosemary or its individual constituents could likely occur at more modest levels of oral intake with less expectation of adverse consequences. Unfortunately, extrapolation of these animal findings to humans is not straightforward. Based on 1 suggested methodology, an approximation of human equivalent doses of rosemary using reported animal doses could be estimated through normalization to body surface area.90 Other guidance for determining human dosing strategies could come from the EFSA and from human studies35,53 in which rosemary powder was given to humans at acute doses of 0.75 to 6.0 g without apparent adverse effects.
Despite EFSA’s conclusions about the safety of rosemary, others have cautioned against the use of higher intakes of individual phytochemicals such as CA for weight loss strategies, because there is evidence that CA and other constituents in rosemary extracts can alter activities of cytochrome P450 enzymes, such as CYP3A4 and CYP2B6, and thus have the potential to affect the metabolism of their substrates.74,75,91–95
Rosmarinus officinalis contains a cocktail of biologically active phytochemicals with diverse health benefits that have only begun to be elucidated. An emerging body of literature supports rosemary as having the potential to improve neurological deficits, inflammatory conditions, and some complications associated with obesity and diabetes. Animal and well-controlled human studies are needed to characterize dose-response relationships for those biological actions that follow dietary administration of rosemary samples at culinary-relevant levels. Specific phytochemicals responsible for any benefits need to be identified along with mechanisms of action and possible toxicities in vivo. In animal models of disease, interactions of dietary rosemary with drug efficacies should be clarified. The composition of rosemary samples used for in vivo investigations must be provided in more detail, and quantitation of blood and tissue markers of rosemary bioavailability would aid in comparisons among experiments.
It also would be valuable to determine whether dietary intake of culinary-relevant levels of rosemary leads to biologically relevant circulating levels of the major rosemary bioactive constituents and whether other dietary factors influence this bioavailability. Such progress in understanding rosemary’s biological activities and in defining dietary rosemary’s health benefits is possible, because preclinical disease models and clinical capabilities to monitor established biomarkers are available.
1. Ulbricht C, Abrams TR, Brigham A, et al. An evidence-based systematic review of rosemary (Rosmarinus officinalis
) by the Natural Standard Research Collaboration. J Diet Suppl
. 2010; 7: 351–413.
2. Al-Sereiti MR, Abu-Amer KM, Sen P. Pharmacology of rosemary (Rosmarinus officinalis
Linn.) and its therapeutic potentials. Ind J Exp Biol
. 1999; 37: 124–130.
3. Mulinacci N, Innocenti M, Bellumori M, Giaccherini C, Martini V, Michelozzi M. Storage method, drying processes and extraction procedures strongly affect the phenolic fraction of rosemary leaves: an HPLC/DAD/MS study. Talanta
. 2011; 85: 167–176.
4. Baldwin N. Inside rosemary’s approval. World Food Ingred
. 2011; Apr/May: 40–41.
5. Cronin H, Draelos ZD. Top 10 botanical ingredients in 2010 anti-aging creams. J Cosmet Dermatol
. 2010; 9: 218–225.
6. Baumann LS. Less-known botanical cosmeceuticals. Dermatol Ther
. 2007; 20: 330–342.
7. Kim HJ, Kim TH, Kang KC, Pyo HB, Jeong HH. Microencapsulation of rosmarinic acid using polycaprolactone and various surfactants. Int J Cosmet Sci
. 2010; 32: 185–191.
8. Fujimoto A, Shingai Y, Nakamura M, Maekawa T, Sone Y, Masuda T. A novel ring-expanded product with enhanced tyrosinase inhibitory activity from classical Fe-catalyzed oxidation of rosmarinic acid, a potent antioxidative Lamiaceae polyphenol. Bioorg Med Chem Lett
. 2010; 20: 7393–7396.
9. European Medicines Agency. Assessment report on Rosmarinus officinalis
L., aetheroleum and Rosmarinus officinalis
L., folium. EMA/HMPG/13631/2009.
10. Faixova Z, Faix S. Biological effects of rosemary (Rosmarinus officinalis
L.) essential oil (a review). Folia Veterin
. 2008; 52: 135–139.
11. Abu-Al-Basal MA. Healing potential of Rosmarinus officinalis
L. on full-thickness excision cutaneous wounds in alloxan-induced-diabetic BALB/c mice. J Ethnopharmacol
. 2010; 131: 443–450.
12. Lakusic D, Ristic M, Slavkovska V, Lakusic B. Seasonal variations in the composition of the essential oils of rosemary (Rosmarinus officinalis
, Lamiaceae). Nat Prod Commun
. 2013; 8: 131–134.
13. Tschiggerl C, Bucar F. Investigation of the volatile fraction of rosemary infusion extracts. Sci Pharm
. 2010; 78: 483–492.
14. Kontogianni VG, Tomic G, Nikolic I, et al. Phytochemical profile of Rosmarinus officinalis
and Salvia officinalis
extracts and correlation to their antioxidant and anti-proliferative activity. Food Chem
. 2013; 136: 120–129.
15. Hsieh CL, Peng CH, Chyau CC, Lin YC, Wang HE, Pend RY. Low-density lipoprotein, collagen, and thrombin models reveal that Rosmarinus officinalis
L. exhibits potent antiglycative effects. J Agric Food Chem
. 2007; 55: 2884–2891.
16. Jin S, Cho KH. Water extracts of cinnamon and clove exhibits potent inhibition of protein glycation and anti-atherosclerotic activity in vitro and in vivo hypolipidemic activity in zebrafish. Food Chem Toxicol
. 2011; 49(7): 1521–1529.
17. Jordán MJ, Lax V, Rota MC, Lorán S, Sotomayor J. Relevance of carnosic acid, carnosol, and rosmarinic acid concentrations in the in vitro antioxidant and antimicrobial activities of Rosmarinus officinalis
(L.) methanolic extracts. J Agric Food Chem
. 2012; 60: 9603–9608.
18. Hossain MB, Rai DK, Brunton NP, Martin-Diana AB, Barry-Ryan C. Characterization of phenolic composition in Lamiaceae spices by LC-ESI-MS/MS. J Agric Food Chem
. 2010; 58: 10576–10581.
19. Ho CT, Wang M, Wei GJ, Huang TC, Huang MT. Chemistry and antioxidative factors in rosemary and sage. Biofactors
. 2000; 13: 161–166.
20. Aquilar F, Autrup H, Barlow S, et al. Scientific Opinion of the Panel on Food Additives, Flavourings, Processing Aids and Materials in Contact With Foods on a request from the Commission on the use of rosemary extracts as a food additive. EFSA J
. 2008; 721: 1–29.
21. Birtić S, Dussort P, Pierre FX P, Bily AC, Roller M. Carnosic acid. Phytochemistry
. 2015; 115: 9–19.
22. Bulgakov VP, Inyushikina YV, Fedoreyev SA. Rosmarinic acid and its derivatives: biotechnology and applications. Crit Rev Biotechnol
. 2012; 32(3): 203–217.
23. Petersen M, Simmonds MS. Rosmarinic acid. Phytochemistry
. 2003; 62: 121–125.
24. Borrás Linares I, Arráez-Román D, Herrero M, Ibáñez E, Segura-Carretero A, Fernández-Gutiérrez A. Comparison of different extraction procedures for the comprehensive characterization of bioactive phenolic compounds in Rosmarinus officinalis
by reversed-phase high-performance liquid chromatography with diode array detection coupled to electrospray time-of-flight mass spectrometry. J Chromatogr A
. 2011; 1218: 7682–7690.
25. Bai N, He K, Roller M, et al. Flavonoids and phenolic compounds from Rosmarinus officinalis
. J Agric Food Chem
. 2010; 58: 5363–5367.
26. del Bano MJ, Lorente J, Castillo J, et al. Phenolic diterpenes, flavones, and rosmarinic acid distribution during the development of leaves, flowers, stems, and roots of Rosmarinus officinalis
. Antioxidant activity. J Agric Food Chem
. 2003; 51: 4247–4253.
27. Vallverdú-Queralt A, Regueiro J, Martínez-Huélamo M, Rinaldi Alvarenga JF, Leal LN, Lamuela-Raventos RM. A comprehensive study on the phenolic profile of widely used culinary herbs and spices: rosemary, thyme, oregano, cinnamon, cumin and bay. Food Chem
. 2014; 154: 299–307.
28. Nabavi SF, Tenore GC, Daglia M, Tundis R, Loizzo MR, Nabavi SM. The cellular protective effects of rosmarinic acid: from bench to bedside. Curr Neurovasc Res
. 2015; 12: 98–105.
29. Lemos M, Lemos M, Pacheco P, Endringer D, Scherer R. Seasonality modifies rosemary’s composition and biological activity. Ind Crops Prod
. 2015; 70: 41–47.
30. Long LH, Hoi A, Halliwell B. Instability of, and generation of hydrogen peroxide by, phenolic compounds in cell culture media. Arch Biochem Biophys
. 2010; 501: 162–169.
31. Razboršek M. Stability studies on trans-rosmarinic acid and GC-MS analysis of its degradation product. J Pharm Biomed Anal
. 2011; 55: 1010–1016.
32. Schwarz K, Ternes W, Schmauderer E. Antioxidative constituents of Rosmarinus officinalis
and Salvia officinalis
. III. Stability of phenolic diterpenes of rosemary extracts under thermal stress as required for technological processes. Z Lebens Unters Forsch
. 1992; 195: 104–107.
33. Baba S, Osakabe N, Natsume M, et al. Absorption, metabolism, degradation and urinary excretion of rosmarinic acid after intake of Perilla frutescens
extract in humans. Eur J Nutr
. 2005; 44: 1–9.
34. Noguchi-Shinohara M, Ono K, Hamaguchi T, et al. Pharmacokinetics, safety and tolerability of Melissa officinalis
extract which contained rosmarinic acid in healthy individuals: a randomized controlled trial. PLoS One
. 2015; 10: e0126422.
35. Percival SS, Vanden Heuvel JP, Nieves CJ. Bioavailability of herbs and spices in humans as determined by ex vivo
inflammatory suppression and DNA breaks. J Am Coll Nutr
. 2012; 31: 288–294.
36. Kelsey NA, Wilkins HM, Linseman DA. Nutraceutical antioxidants as novel neuroprotective agents. Molecules
. 2010; 15: 7792–7814.
37. Park SE, Kim S, Sapkota K, Kim SJ. Neuroprotective effect of Rosmarinus officinalis
extract on human dopaminergic cell line, SH-SY5Y. Cell Mol Neurobiol
. 2010; 30: 759–767.
38. Mazzio E, Huber J, Darling S, Harris N, Soliman KF. Effect of antioxidants on l-glutamate and N
-methyl-4-phenylpyridinium ion induced-neurotoxicity in PC12 cells. Neurotoxicology
. 2001; 22: 283–288.
39. Koutroumanidou E, Kimbaris A, Kortsaris A, et al. Increased seizure latency and decreased severity of pentylenetetrazol-induced seizures in mice after essential oil administration. Epilepsy Res Treat
. 2013; 2013: 532657.
40. Lavrentiadou SN, Tsantarliotou MP, Zervos IA, Nikolaidis E, Georgiadis MP, Taitzoglou IA. CCl4
induces tissue-type plasminogen activator in rat brain; protective effects of oregano, rosemary or vitamin E. Food Chem Toxicol
. 2013; 61: 196–202.
41. Gedney JJ, Glover TL, Fillingim RB. Sensory and affective pain discrimination after inhalation of essential oils. Psychosom Med
. 2004; 66: 599–606.
42. Lukaczer D, Darland G, Tripp M, et al. A pilot trial evaluating Meta050, a proprietary combination of reduced iso-alpha acids, rosemary extract and oleanolic acid in patients with arthritis and fibromyalgia. Phytother Res
. 2005; 19: 864–869.
43. Kennedy DO, Scholey AB. The psychopharmacology of European herbs with cognition-enhancing properties. Curr Pharm Des
. 2006; 12: 4613–4623.
44. Atsumi T, Tonosaki K. Smelling lavender and rosemary increases free radical scavenging activity and decreases cortisol level in saliva. Psych Res
. 2007; 150: 89–96.
45. McCaffrey R, Thomas DJ, Kinzelman AO. The effects of lavender and rosemary essential oils on test-taking anxiety among graduate nursing students. Holist Nurs Pract
. 2009; 23: 88–93.
46. Burnett KM, Solterbeck LA, Strapp CM. Scent and mood state following an anxiety-provoking task. Psychol Rep
. 2004; 95: 707–722.
47. Diego MA, Jones NA, Field T, et al. Aromatherapy positively affects mood, EEG patterns of alertness and math computations. Int J Neurosci
. 1998; 96: 217–224.
48. Sanders C, Diego M, Fernandez M, Field T, Hernandez-Reif M, Roca A. EEG asymmetry responses to lavender and rosemary aromas in adults and infants. Int J Neurosci
. 2002; 112: 1305–1320.
49. Lindheimer JB, Loy BD, O’Connor PJ. Short-term effects of black pepper (Piper nigrum
) and rosemary (Rosmarinus officinalis
and Rosmarinus eriocalyx
) on sustained attention and on energy and fatigue mood states in young adults with low energy. J Med Food
. 2013; 16: 765–771.
50. Moss M, Cook J, Wesnes K, Duckett P. Aromas of rosemary and lavender essential oils differentially affect cognition and mood in healthy adults. Int J Neurosci
. 2003; 113: 15–38.
51. Ball LJ, Shoker J, Miles JN. Odour-based context reinstatement effects with indirect measures of memory: the curious case of rosemary. Br J Psychol
. 2010; 101: 655–678.
52. Jimbo D, Kimura Y, Taniguchi M, Inoue M, Urakami K. Effect of aromatherapy on patients with Alzheimer’s disease. Psychogeriatrics
. 2009; 9: 173–179.
53. Pengelly A, Snow J, Mills SY, Scholey A, Wesnes K, Butler LR. Short-term study on the effects of rosemary on cognitive function in an elderly population. J Med Food
. 2012; 15: 10–17.
54. Sayorwan W, Ruangrungsi N, Piriyapunyporn T, Hongratanaworakit T, Kotchabhakdi N, Siripornpanich V. Effects of inhaled rosemary oil on subjective feelings and activities of the nervous system. Sci Pharm
. 2013; 81: 531–542.
55. Takaki I, Bersani-Amado LE, Vendruscolo A, et al. Anti-inflammatory and antinociceptive effects of Rosmarinus officinalis
L. essential oil in experimental animal models. J Med Food
. 2008; 11: 741–746.
56. Nogueira de Melo GA, Grespan R, Fonseca JP, et al. Rosmarinus officinalis
L. essential oil inhibits in vivo
and in vitro leukocyte migration. J Med Food
. 2011; 14: 944–946.
57. Inoue K, Takano H, Shiga A, et al. Effects of volatile constituents of rosemary extract on lung inflammation induced by diesel exhaust particles. Basic Clin Pharmacol Toxicol
. 2006; 99: 52–57.
58. Inoue K, Takano H, Shiga A, et al. Effects of volatile constituents of a rosemary extract on allergic airway inflammation related to house dust mite allergen in mice. Int J Mol Med
. 2005; 16: 315–319.
59. Minich DM, Bland J, Katke J, et al. Clinical safety and efficacy of NG440: a novel combination of rho iso-alpha acids from hops, rosemary, and oleanolic acid for inflammatory conditions. Can J Physiol Pharmacol
. 2007; 85: 872–883.
60. Connelly AE, Tucker AJ, Tulk H, et al. High-rosmarinic acid spearmint tea in the management of knee osteoarthritis symptoms. J Med Food
. 2014; 17: 1361–1367.
61. Lee J, Jung E, Koh J, Kim YS, Park D. Effect of rosmarinic acid on atopic dermatitis. J Dermatol
. 2008; 35: 768–771.
62. Osakabe N, Takano H, Sanbongi C, et al. Anti-inflammatory and anti-allergic effect of rosmarinic acid (RA); inhibition of seasonal allergic rhinoconjunctivitis (SAR) and its mechanism. BioFactors
. 2004; 21: 127–131.
63. Takano H, Osakabe N, Sanbongi C, et al. Extract of Perilla frutescens
enriched for rosmarinic acid, a polyphenolic phytochemical, inhibits seasonal allergic rhinoconjunctivitis in humans. Exp Biol Med
. 2004; 229: 247–254.
64. Worth H, Schacher C, Dethlefsen U. Concomitant therapy with cineole (eucalyptole) reduces exacerbations in COPD: a placebo-controlled double-blind trial. Respir Res
. 2009; 10: 69–75.
65. Juergens UR, Dethlefsen U, Steinkamp G, Gillisen A, Repges R, Vetter H. Anti-inflammatory activity of 1.8-cineol (eucalyptol) in bronchial asthma: a double-blind placebo-controlled trial. Respir Med
. 2003; 97: 250–256.
66. Juergens UR, Stöber M, Schmidt-Schilling L, Kleuver T, Vetter H. Antiinflammatory effects of euclyptol (1.8-cineole) in bronchial asthma: inhibition of arachidonic acid metabolism in human blood monocytes ex vivo. Eur J Med Res
. 1998; 3: 407–412.
67. Juergens UR, Stöber M, Vetter H. Inhibition of cytokine production and arachidonic acid metabolism by eucalyptol (1.8-cineole) in human blood monocytes in vitro. Eur J Med Res
. 1998; 3: 508–510.
68. Altinier G, Sosa S, Aquino RP, Mencherini T, Della Loggia R, Tubaro A. Characterization of topical antiinflammatory compounds in Rosmarinus officinalis L
. J Agric Food Chem
. 2007; 55: 1718–1723.
69. Erenmemisoglu A, Sarayan R, Ustun S. Effect of a Rosmarinus officinalis
leave extract on plasma glucose levels in normoglycaemic and diabetic mice. Pharmazie
. 1997; 52: 645–646.
70. Bakirel T, Bakirel U, Keleş OU, Ulgen SG, Yardibi H. In vivo
assessment of antidiabetic and antioxidant activities of rosemary (Rosmarinus officinalis
) in alloxan-diabetic rabbits. J Ethnopharmacol
. 2008; 116: 64–73.
71. Nazem F, Farhangi N, Neshat-Gharameleki M. Beneficial effect of endurance exercise with Rosmarinus officinalis
Labiatae leaves extract on blood antioxidant enzyme activities and lipid peroxidation in streptozotocin-induced diabetic rats. Can J Diabetes
. 2015; 39: 229–234.
72. Ibarra A, Cases J, Roller M, Chiralt-Boix A, Coussaert A, Ripoll C. Carnosic acid-rich rosemary (Rosmarinus officinalis L
.) leaf extract limits weight gain and improves cholesterol levels and glycaemia in mice on a high-fat diet. Br J Nutr
. 2011; 106: 1182–1189.
73. Romo Vaquero M, Yáñez-Gascón M, García Villalba R, et al. Inhibition of gastric lipase as a mechanism for body weight and plasma lipids reduction in Zucker rats fed a rosemary extract rich in carnosic acid. PLoS One
. 2012; 7: e39773.
74. Debersac P, Heydel JM, Amiot MJ, et al. Induction of cytochrome P450 and/or detoxication enzymes by various extracts of rosemary: description of specific patterns. Food Chem Toxicol
. 2001; 39: 907–918.
75. Debersac P, Vernevaut M, AMiot M, et al. Effects of a water-soluble extract of rosemary and its purified compound rosmarinic acid on xenobiotic-metabolizing enzymes in rat liver. Food Chem Toxicol
. 2001; 39: 109–117.
76. Greenhill C. Carnosic acid could be a new treatment option for patients with NAFLD or the metabolic syndrome. Nat Rev Gastroenterol Hepatol
. 2011; 8: 122.
77. Romo-Vaquero M, Larrosa M, Yáñez-Gascón M, et al. A rosemary extract enriched in carnosic acid improves circulating adipocytokines and modulates key metabolic sensors in lean Zucker rats: critical and contrasting differences in the obese genotype. Mol Nutr Food Res
. 2014; 58: 942–953.
78. Stefanon B, Pomari E, Colitti M. Effects of Rosmarinus officinalis
extract on human primary omental preadipocytes and adipocytes. Exp Biol Med
). 2015; 240(7): 884–895.
79. Romo-Vaquero M, Selma MV, Larrosa M, et al. A rosemary extract rich in carnosic acid selectively modulates caecum microbiota and inhibits β-glucosidase activity, altering fiber and short chain fatty acids fecal excretion in lean and obese female rats. PLoS One
. 2014; 9(4): e94687.
80. Harach T, Aprikian O, Monnard I, Moulin J, et al. Rosemary (Rosmarinus officinalis L
.) leaf extract limits weight gain and liver steatosis in mice fed a high-fat diet. Planta Med
. 2010; 76: 566–571.
81. Zhao Y, Sedighi R, Wang P, Chen H, Zhu Y, Sang S. Carnosic acid as a major bioactive component in rosemary extract ameliorates high-fat-diet–induced obesity and metabolic syndrome in mice. J Agric Food Chem
. 2015; 63: 4843–4852.
82. Park MY, Sung MK. Carnosic acid attenuates obesity-induced glucose intolerance and hepatic fat accumulation by modulating genes of lipid metabolism in C57BL/6J-ob/ob mice. J Sci Food Agric
. 2015; 95: 828–835.
83. Sedighi R, Zhao Y, Yerke A, Sang S. Preventive and protective properties of rosemary (Rosmarinus officinalis
L.) in obesity and diabetes mellitus of metabolic disorders: a brief review. Curr Opin Food Sci
. 2015; 2: 58–70.
84. Balderas C, Villaseñor A, García A, et al. Metabolomic approach to the nutraceutical effect of rosemary extract plus Ω-3 PUFAs in diabetic children with capillary electrophoresis. J Pharmaceut Biomed Anal
. 2010; 53: 1298–1304.
85. Godzien J, Ciborowski M, Angulo S, et al. Metabolomic approach with LC-QTOF to study the effect of a nutraceutical treatment on urine of diabetic rats. J Prot Res
. 2011; 10: 837–844.
86. Godzien J, Ciborowski M, Angulo S, Barbas C. From numbers to a biological sense: how the strategy chosen for metabolomics data treatment may affect final results. A practical example based on urine fingerprints obtained by LC-MS. Electrophoresis
. 2013; 34: 2812–2826.
87. Skulas-Ray AC, Kris-Etherton PM, Teeter DL, Chen CY, Vanden Heuvel JP, West SG. A high antioxidant spice blend attenuates postprandial insulin and triglyceride responses and increases some plasma measures of antioxidant activity in healthy, overweight men. J Nutr
. 2011; 141: 1451–1457.
88. Parnham M, Kesselring K. Rosmarinic acid. Drugs Future
. 1985; 10: 756–757.
89. Anadón A, Martínez-Larrañaga M, Martínez M, et al. Acute oral safety study of rosemary extracts in rats. J Food Prot
. 2008; 71: 790–795.
90. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J
. 2008; 22: 659–661.
91. Greenlee H, Atkinson C, Stanczyk FZ, Lampe JW. A pilot and feasibility study on the effects of naturopathic botanical and dietary interventions on sex steroid hormone metabolism in premenopausal women. Cancer Epidemiol Biomarkers Prev
. 2007; 16: 1601–1609.
92. Zhang W, Lim LY. Effects of spice constituents on P-glycoprotein-mediated transport and CYP3A4-mediated metabolism in vitro. Drug Metab Dispos
. 2008; 36: 1283–1290.
93. Jori A, Bianchetti A, Prestini PE, Gerattini S. Effect of eucalyptol (1,8-cineole) on the metabolism of other drugs in rats and in man. Eur J Pharmacol
. 1970; 9: 362–366.
94. Healthline. Rosemary (Rosmarinus officinalis
Linn.). Available at: http://www.healthline.com/natstamdardcontent/rosemary
. Accessed June 13, 2012.
95. Dickmann L, VandenBrink B, Lin Y. In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with anti-adipogenic properties. Drug Metabol Disp
. 2012; 40: 1263–1267.